| Literature DB >> 32345712 |
Anne Marie Lennon1,2,3, Adam H Buchanan4, Isaac Kinde5, Andrew Warren5,6, Ashley Honushefsky4, Ariella T Cohain5, David H Ledbetter4, Fred Sanfilippo7, Kathleen Sheridan4, Dillenia Rosica4, Christian S Adonizio4,8, Hee Jung Hwang5, Kamel Lahouel1,9, Joshua D Cohen1,2,10,11,12, Christopher Douville1,11, Aalpen A Patel4, Leonardo N Hagmann5, David D Rolston4, Nirav Malani5, Shibin Zhou1,11, Chetan Bettegowda1,11,13, David L Diehl4, Bobbi Urban5, Christopher D Still4, Lisa Kann5, Julie I Woods4, Zachary M Salvati4, Joseph Vadakara4, Rosemary Leeming4, Prianka Bhattacharya4, Carroll Walter4, Alex Parker5, Christoph Lengauer5,6, Alison Klein1,2,14, Cristian Tomasetti1,9,15, Elliot K Fishman1,2,16, Ralph H Hruban1,2,17, Kenneth W Kinzler18,2,11, Bert Vogelstein18,2,10,11, Nickolas Papadopoulos18,2,11,17.
Abstract
Cancer treatments are often more successful when the disease is detected early. We evaluated the feasibility and safety of multicancer blood testing coupled with positron emission tomography-computed tomography (PET-CT) imaging to detect cancer in a prospective, interventional study of 10,006 women not previously known to have cancer. Positive blood tests were independently confirmed by a diagnostic PET-CT, which also localized the cancer. Twenty-six cancers were detected by blood testing. Of these, 15 underwent PET-CT imaging and nine (60%) were surgically excised. Twenty-four additional cancers were detected by standard-of-care screening and 46 by neither approach. One percent of participants underwent PET-CT imaging based on false-positive blood tests, and 0.22% underwent a futile invasive diagnostic procedure. These data demonstrate that multicancer blood testing combined with PET-CT can be safely incorporated into routine clinical care, in some cases leading to surgery with intent to cure.Entities:
Mesh：
Year: 2020 PMID： 32345712 PMCID： PMC7509949 DOI： 10.1126/science.abb9601
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728